Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?

被引:10
|
作者
Tachibana, Masahiro [1 ]
Yonemoto, Yukio [1 ]
Okamura, Koichi [1 ]
Suto, Takahito [1 ]
Sakane, Hideo [1 ]
Kaneko, Tetsuya [1 ]
Dam, Trang Thuy [1 ,2 ,3 ]
Okura, Chisa [1 ]
Tajika, Tsuyoshi [1 ]
Tsushima, Yoshito [3 ,4 ]
Chikuda, Hirotaka [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Orthopaed Surg, Showa Machi 3-39-15, Maebashi, Gunma 3718511, Japan
[2] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol & Nucl Med, Showa Machi 3-39-15, Maebashi, Gunma 3718511, Japan
[3] Bach Mai Hosp, Radiol Ctr, Hanoi, Vietnam
[4] Gunma Univ Initiat Adv Res GIAR, Res Program Diagnost & Mol Imaging, Div Integrated Oncol Res, Maebashi, Gunma, Japan
关键词
Periodontitis; FDG-PET; CT; Biologic therapy; Rheumatoid arthritis; Treatment response; LARGE-JOINT DESTRUCTION; F-18-FDG ACCUMULATION; DISEASE; ASSOCIATION; IMMUNOTHERAPY; INFLAMMATION; ANTIBODIES; PET/CT;
D O I
10.1186/s13075-020-02269-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Rheumatoid arthritis (RA) and periodontitis (PD) have been suggested to share many clinical and pathological features. However, few reports have investigated the relationship between the degree of PD and the treatment response to RA. This study aimed to examine the relationship between the extent of PD and the treatment response to biologics in RA patients using FDG-PET/CT. Methods Sixty RA patients (male,n = 14; female,n = 46; average age, 58.3 years) treated with biologic agents were included in this study. FDG-PET/CT was performed at baseline and 6 months after the initiation of biological therapy. The maximum standardized uptake value (SUVmax) was used as a representative value for the assessment of the FDG uptake in periodontal tissue and joints including the bilateral shoulders, elbows, wrists, hip, knees, and ankle joints. The Disease Activity Score (DAS) 28-CRP and the following clinical parameters were assessed: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), anti-cyclic citrullinated peptide antibody (ACPA), rheumatoid factor (RF), and matrix metalloproteinase 3 (MMP-3). The relationship between the treatment response of RA and the baseline SUVmax of the periodontal tissue was evaluated. Results The baseline periodontal SUVmax was related to patient age (r = 0.302,p = 0.009) and the ACPA level (r = 0.265,p = 0.025). The DAS28-CRP, CRP, ESR, MMP-3, and joint SUVmax values were significantly decreased after 6 months of biological therapy. However, the mean periodontal SUVmax, ACPA, and RF showed no significant changes after treatment. There was a significantly negative correlation between the baseline periodontal SUVmax and the treatment response of DAS28-CRP (r = - 0.369,p = 0.004). Conclusion There was a negative correlation between the extent of PD at baseline and the treatment response of RA patients who received biological therapy. The evaluation of the periodontal condition is considered to be an essential part for the management of RA.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?
    Masahiro Tachibana
    Yukio Yonemoto
    Koichi Okamura
    Takahito Suto
    Hideo Sakane
    Tetsuya Kaneko
    Trang Thuy Dam
    Chisa Okura
    Tsuyoshi Tajika
    Yoshito Tsushima
    Hirotaka Chikuda
    Arthritis Research & Therapy, 22
  • [2] Cigarette Smoking Does Not Affect Treatment Response to Tofacitinib in Rheumatoid Arthritis
    Karatas, Ahmet
    Oz, Burak
    Dalkilic, Ediz
    Can, Gercek
    Pehlivan, Yavuz
    Senel, Soner
    Yazici, Ayten
    Inanc, Nevsun
    Erturk, Zeynep
    Cefle, Ayse
    Akar, Servet
    Koca, Suleyman Serdar
    Birlik, Merih
    Onen, Fatos
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [3] Treatment of rheumatoid arthritis with biologics
    Panayi, GS
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1996, 126 : S22 - S23
  • [4] BIOMARKERS FOR EARLY TREATMENT RESPONSE TO BIOLOGICS IN TREATMENT OF RHEUMATOID ARTHRITIS.
    Zhang, Lijun
    Zhang, Li
    Amur, Shashi
    Siegel, Jeff
    Ding, Xiao
    Lau, Olivia
    Rochester, George
    Tornoe, Christoffer W.
    Doddapaneni, Suresh
    Sahajwalla, Chandrahas
    Nallani, Srikanth C.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1083 - 1083
  • [5] Treatment of rheumatoid arthritis and spondylarthritis with biologics
    Fiehn, Christoph
    INTERNIST, 2022, 63 (02): : 135 - 142
  • [6] TREATMENT OF RHEUMATOID ARTHRITIS - COMPARATIVE EFFECTIVENESS OF BIOLOGICS
    Schiffner-Rohe, J.
    Leverkus, F.
    Behmer, O. S.
    Kerkmann, U.
    VALUE IN HEALTH, 2012, 15 (07) : A461 - A461
  • [7] Cost effectiveness of biologics in the treatment of rheumatoid arthritis
    Müller-Ladner, U
    INTERNIST, 2004, 45 (12): : 1402 - 1406
  • [8] The Role of Biologics in The Treatment of Rheumatoid Arthritis: A Review
    Bookya, Kishan
    Balaji, Bairam
    Kathyayani, R.
    Mangilal, Teelavath
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES, 2015, 4 (04): : 1 - 8
  • [9] THE FUTURE OF BIOLOGICS IN THE TREATMENT OF RHEUMATOID-ARTHRITIS
    KOOPMAN, WJ
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1994, 23 (06) : 50 - 58
  • [10] The use of biologics in the treatment of rheumatoid arthritis (RA)
    Manolios, N
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1997, 27 (05): : 607 - 607